CD70 and neoplasm: Data from a Her-2-positive syngeneic mouse tumor model in immunocompetent mice also support a role for mIL-21 stimulating NK cells to produce IFN-γ and enhancing antibody therapy [31], and studies of a Raji lymphoma model with a chimeric anti-CD70 monoclonal antibody also found NK cells important for prolonging survival [32].